rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Gregory S. Curhan

Chief Financial Officer

Company insider

Files Form 4 as: Chief Financial Officer, Serina Therapeutics; Officer, Elicio Therapeutics; Director, Power Efficiency; Executive Vice President, Merriman Curhan Ford Group.

In numbers

Trades disclosed
23
Buys
1
Sells
0
Bought
$9,480
Sold
$0
Companies
4
Companies where not an officer
1
First trade
8 Jun 2007
Last trade
21 May 2026
Last filed
26 May 2026

Companies traded

Where they are an officer
SER Serina TherapeuticsOfficer · Biotechnology · last 21 May 20260 buys · 0 sells
ELTX Elicio TherapeuticsOfficer · Biotechnology · last 2 Mar 20221 buy · 0 sells
Merriman Curhan Ford GroupOfficer · last 31 Oct 20080 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
Power EfficiencyDirector · last 11 Mar 20090 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
21 May 2026filed 26 May 2026SER Serina Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—123,019 at $0.00filing
21 May 2026filed 26 May 2026SER Serina Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—123,019 at $0.00filing
15 Aug 2024filed 20 Aug 2024SER Serina Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—250,000 at $0.00filing
2 Mar 2022filed 4 Mar 2022ELTX Elicio Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—100,000 at $0.00filing
15 Dec 2021filed 16 Dec 2021ELTX Elicio TherapeuticsBiotechnologySEC FORM 4 Bought$9,4804,000 at $2.37filing
11 Mar 2009filed 13 Mar 2009Power Efficiencyoption or derivativeSEC FORM 4 Code A$11K100,000 at $0.11filing
11 Mar 2009filed 13 Mar 2009Power Efficiencyoption or derivativeSEC FORM 4 Code A$40K360,000 at $0.11filing
31 Oct 2008filed 5 Nov 2008Merriman Curhan Ford Groupoption or derivativeSEC FORM 4 Code J$530K142,858 at $3.71filing
31 Oct 2008filed 5 Nov 2008Merriman Curhan Ford Groupoption or derivativeSEC FORM 4 Code J$1.5M442,858 at $3.29filing
31 Oct 2008filed 5 Nov 2008Merriman Curhan Ford Groupoption or derivativeSEC FORM 4 Code J$48K10,000 at $4.82filing
31 Oct 2008filed 5 Nov 2008Merriman Curhan Ford Groupoption or derivativeSEC FORM 4 Code J$48K10,000 at $4.82filing
31 Oct 2008filed 5 Nov 2008Merriman Curhan Ford Groupoption or derivativeSEC FORM 4 Code J$289K60,000 at $4.82filing
31 Oct 2008filed 5 Nov 2008Merriman Curhan Ford Groupoption or derivativeSEC FORM 4 Code J$57K10,000 at $5.69filing
31 Oct 2008filed 5 Nov 2008Merriman Curhan Ford Groupoption or derivativeSEC FORM 4 Code J$14K3,750 at $3.84filing
31 Oct 2008filed 5 Nov 2008Merriman Curhan Ford Groupoption or derivativeSEC FORM 4 Code J$14K3,750 at $3.84filing
31 Oct 2008filed 5 Nov 2008Merriman Curhan Ford Groupoption or derivativeSEC FORM 4 Code J$506.3M22,500 at $22,500.00filing
2 May 2008filed 6 May 2008Mcfoption or derivativeSEC FORM 4 Code A$86K22,500 at $3.84filing
2 May 2008filed 6 May 2008Mcfoption or derivativeSEC FORM 4 Code A$14K3,750 at $3.84filing
2 May 2008filed 6 May 2008Mcfoption or derivativeSEC FORM 4 Code A$14K3,750 at $3.84filing
11 Feb 2008filed 19 Feb 2008Mcfoption or derivativeSEC FORM 4 Code A$57K10,000 at $5.69filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care1

Buys in green, sells in red, by the company’s sector.

Related people

Jay VenkatesanDirector · Director at Elicio Therapeutics, filing Form 4 there in the last year
Carol Gail AsheDirector · Director at Elicio Therapeutics, filing Form 4 there in the last year
Robert R. RuffoloDirector · Director at Elicio Therapeutics, filing Form 4 there in the last year
Julian AdamsDirector · Director at Elicio Therapeutics, filing Form 4 there in the last year
Karen J. WilsonDirector · Director at Elicio Therapeutics, filing Form 4 there in the last year